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OBJECTIVE—Insulin resistance might play a role in the patho-
genesis of polycystic ovarian syndrome (PCOS). The family of
glycoprotein 130 (gp130) cytokines could inﬂuence insulin ac-
tion. One of these cytokines is interleukin (IL)-6, which exerts a
short-term insulin-sensitizing effect, whereas in a long-term pe-
riod, it might induce insulin resistance. Some other gp130 acti-
vators are supposed to have beneﬁcial metabolic effects. Gp130
is present in the circulation in the soluble form (sgp130), which
inhibits intracellular gp130 signaling. The aim of the present
study was to estimate the relation between sgp130 and insulin
sensitivity in women with PCOS.
RESEARCH DESIGN AND METHODS—We studied 78 women
with PCOS (35 lean and 43 obese) and 34 healthy women (18 lean
and 16 obese). The euglycemic-hyperinsulinemic clamp and the
measurements of serum sgp130, IL-6, soluble IL-6 receptor (sIL-6R),
and sex hormones were performed.
RESULTS—Both obesity and PCOS were characterized by an
increased sgp130 (P  0.0001 and P  0.0002, respectively).
sIL-6R concentration was lower (P  0.0036) in women with
PCOS independently of obesity. Serum sgp130 was negatively
correlated with insulin sensitivity when control and PCOS
women were analyzed together (r  0.36, P  0.0001) and in
the PCOS subjects separately (r  0.34, P  0.002). In multiple
regression analysis, this correlation was signiﬁcant after adjust-
ment for BMI, waist, percent of body fat, postload glucose and
insulin, triglycerides, and high-sensitive C-reactive protein.
CONCLUSIONS—Serum sgp130 is inversely and independently
associated with insulin sensitivity in women with PCOS. An
increased serum sgp130 in obesity and PCOS suggests an
inhibition of intracellular gp130 signaling in insulin-resistant
conditions. Diabetes 59:1026–1029, 2010
P
olycystic ovarian syndrome (PCOS) is a common
endocrine disorder with a diverse and heteroge-
neous nature that is present in 5–10% of repro-
ductive-age women. PCOS is characterized by
hyperandrogenism and chronic anovulation (1,2). Insulin
resistance is a common feature of PCOS and might be the
cause of signiﬁcant metabolic and cardiovascular compli-
cations observed in this condition (3).
The family of glycoprotein 130 (gp130) cytokines might
inﬂuence insulin action (4). This family includes interleu-
kin (IL)-6, IL-11, leukemia inhibitory factor, ciliary neuro-
trophic factor, oncostatin, and cardiotrophin-1 (5). Gp130
cytokines play a pivotal role in the regulation of the
immune, hematopoietic, nervous, cardiovascular, and en-
docrine systems (5). These cytokines exert their actions
through a heterodimeric or homodimeric receptor consist-
ing of two membrane-bound glycoproteins: a cytokine
binding subunit and a glycoprotein termed IL-6 transducer,
or IL6ST, also known as gp130, which is responsible for
signal transduction (6).
IL-6 was thought to be an insulin-desensitizing factor
(7). However, it might have some beneﬁcial metabolic
actions, and it was hypothesized that it exerts a short-term
insulin-sensitizing effect, whereas in the long-term period,
IL-6 might induce insulin resistance (8). IL-6 increased
glycogen synthesis and enhanced lipid oxidation via an
AMP-activated protein kinase (AMPK)-dependent mech-
anism in skeletal muscle (9). Another gp130 cytokine,
ciliary neurotrophic factor, prevented weight gain and
stimulated AMPK in skeletal muscle (10). Therefore, it is
supposed that gp130 activators might be useful in the
treatment of obesity and insulin resistance (4). Gp130 is
expressed in most cells of the body (6) and is present in
the circulation in soluble form (sgp130), which inhibits
intracellular gp130 signaling (11). The role of sgp130 in
the pathogenesis of human insulin resistance has not
been studied so far.
Soluble form of the IL-6R (sIL-6R) occurs in various
body ﬂuids and might induce gp130 dimerization and
signaling when complexed with IL-6. The presence of
sIL-6R leads to sensitization of IL-6–responsive cells to-
ward the ligand (12). The IL-6/sIL-6R complex stimulates
several types of cells that only express gp130 and are
unresponsive to IL-6 alone. This process is called trans-
signaling (13). Sgp130 exerts also inhibitory effects toward
the IL-6/sIL-6R complex (14).
We hypothesized that serum spg130 might be altered in
insulin-resistant conditions in humans and might be re-
lated to insulin sensitivity. To test this hypothesis, we
studied serum sgp130, IL-6, and sIL-6R in relation to
insulin sensitivity in lean and obese women with PCOS
and BMI-matched healthy control subjects.
RESEARCH DESIGN AND METHODS
The study group consisted of 78 women with PCOS (35 lean, BMI 25 kg/m
2,
and 43 overweight or obese, BMI 25 kg/m
2) and 34 healthy normally
menstruating women (18 lean and 16 overweight or obese). The subjects’
recruitment and diagnosis of PCOS according to Rotterdam criteria (15) was
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1026 DIABETES, VOL. 59, APRIL 2010 diabetes.diabetesjournals.orgdescribed in detail previously (16). Before entering the study, a physical
examination and appropriate laboratory test were performed. A standard 75-g
oral glucose tolerance test was performed, and all participants had normal
glucose tolerance. None of the women had morbid obesity (BMI 40 kg/m
2),
cardiovascular disease, hypertension, infections, or other serious medical
problems; all were nonsmokers, and they were not taking any anti-inﬂamma-
tory drugs and drugs known to affect glucose and lipid metabolism. Studies
were performed in the PCOS group 3–5 days after a spontaneous menses or
independent of cycle phase in the presence of amenorrhea and in regularly
cycling women during the early follicular phase (3–5 days) of their menstrual
cycle. All analyses were performed after an overnight fast. The study protocol
was approved by the ethics committee of the Medical University of Białystok,
Poland. All participants gave written informed consent before entering the
study. Anthropometric measurements were performed as previously de-
scribed (16).
Insulin sensitivity. Insulin sensitivity was evaluated by the euglycemic-
hyperinsulinemic clamp technique as previously described (16). The rate of
whole-body glucose uptake (M value) was calculated as the mean glucose
infusion rate from 80 to 120 min, corrected for glucose space and normalized
per kilogram of fat-free mass (M/FFM).
Biochemical analyses. Plasma glucose was measured immediately by the
enzymatic method using a glucose analyzer (YSI 2300 STAT Plus; Yellow
Springs Instruments, Yellow Springs, OH). The serum insulin was measured
with immunoradiometric assay with the sensitivity of 1 IU/ml and intra- and
interassay coefﬁcients of variation (CVs) 2.2 and 6.5%, respectively (Bio-
Source Europe, Nivelles, Belgium). Serum lipids were measured as previously
described (16).
Before estimation of serum insulin, sgp130, IL-6, and sIL6-R, samples were
kept frozen at 80°C. Serum sgp130 was measured with a quantitative
sandwich enzyme immunoassay kit (ELISA) (R&D Systems, Minneapolis, MN)
with the lowest detectable limit of 0.08 ng/ml and with intra- and interassay
CVs below 5.5 and 5.2%, respectively. Serum high-sensitivity IL-6 (hsIL-6) and
sIL-6R concentrations were determined with ELISA kits (R&D Systems). The
minimum detectable concentration was 0.039 pg/ml for hsIL-6 and 6.5 pg/ml
for sIL-6R. Intra- and interassay CVs were, respectively, 7.8 and 9.6% for
hsIL-6 and 8.6 and 9.6% for sIL-6R. Serum high-sensitive C-reactive protein
(hsCRP) was measured by means of particle enhanced immunonephelometry
using a CardioPhase kit (Dade Behring, Marburg, Germany) with a sensitivity
of 0.175 mg/l and intra- and interassay CVs 4.5 and 5.8%, respectively.
Serum luteinizing hormone, follicle-stimulating hormone, testosterone,
and estradiol were measured by the chemiluminescence method (ACS
Chirone 180), and serum sex hormone–binding globulin (SHBG) was
measured by the immunoradiometric assay (ZenTech, Angleur, Belgium).
The sensitivity and CVs for all these assays were identical, as reported
previously (16). Free androgen index was calculated as serum testosterone
(nmol/l)  100/SHBG (nmol/l) ratio (17).
Statistical analysis. The statistics were performed with STATISTICA 8.0
software. The variables, which did not have normal distribution (fasting
and postload insulin, triglycerides, IL-6, sIL-6R, sgp130, SHBG, testosterone,
free androgen index, estradiol, and hsCRP) were log-transformed before the
analyses. For the purpose of the data presentation, these variables were
transformed to absolute values in the RESULTS. The differences between the
groups were estimated with factorial ANOVA, with PCOS status and obesity as
categorical factors and the studied parameters as dependent variables. The
relationships between variables were studied with the Pearson product-
moment correlation analysis and with multiple regression analysis. The level
of signiﬁcance was accepted at P  0.05.
RESULTS
The clinical characteristics of the studied groups is shown
in Table 1. In the factorial ANOVA, we observed that the
PCOS women had higher serum sgp130 concentrations
than the control group (P  0.0002). We also found that
the obese women had higher serum sgp130 concentrations
than the lean women (P  0.0001). The interaction
between PCOS status and obesity was not signiﬁcant (P 
0.29), which suggests that an increase in sgp130 in PCOS
was independent of obesity and an increase in sgp130 in
obesity was independent of PCOS status. Additionally,
PCOS women had signiﬁcantly lower serum sIL-6R (P 
0.0036). In contrast, serum sIL-6R did not differ between
lean and obese women (P  0.93). Serum IL-6 and hsCRP
did not differ between PCOS and control subjects, whereas
they were increased in the obese group compared with the
lean group (P  0.007 and P  0.001, respectively).
Both the presence of PCOS and obesity were indepen-
dently characterized by lower insulin sensitivity (P 
0.0021 and P  0.0033, respectively; P  0.62 for the
interaction), lower serum SHBG (P  0.011 and P 
0.0001, respectively; P  0.22 for the interaction), and
higher free androgen index (both P  0.0001, P  0.34 for
the interaction). PCOS women also had higher serum
luteinizing hormone and testosterone concentrations
(both P  0.0001) (Table 2).
Cross-sectionally, serum sgp130 was related to BMI (r 
0.35, P  0.001), waist (r  0.36, P  0.001), body fat (r 
TABLE 1
Clinical and biochemical characteristics of the studied groups
Lean Obese
P (obesity/PCOS) Control PCOS Control PCOS
n 18 35 16 43
Age (years) 26.33  5.56 24.11  3.94 27.44  5.27 25.60  5.57 NS
BMI (kg/m
2) 22.19  1.92 21.71  1.81 30.66  4.37 31.46  4.34 0.001/NS
Waist (cm) 73.72  5.50 72.66  6.95 94.13  10.95 94.36  12.57 0.001/NS
Body fat (%) 21.97  5.71 24.76  6.84 37.79  9.03 37.90  10.84 0.001/NS
Fasting glucose (mg/dl) 80.82  6.20 80.22  8.21 81.08  6.98 86.00  7.28 NS
Postload glucose (mg/dl) 81.31  15.40 82.22  15.31 92.68  20.24 97.28  23.09 0.0013/NS
Fasting insulin (IU/ml) 8.44  3.21 11.80  5.95 14.33  5.30 16.14  9.58 0.001/NS
Postload insulin (IU/ml) 31.28  15.90 40.17  25.88 48.37  37.37 82.01  92.34 0.014/NS
Cholesterol (mg/dl) 186.68  36.83 181.06  36.16 173.25  40.97 185.78  38.66 NS
Triglycerides (mg/dl) 66.92  21.44 70.40  34.06 105.83  103.47 103.27  54.74 0.005/NS
HDL cholesterol (mg/dl) 56.35  12.73 62.99  13.73 57.16  9.02 50.23  9.56 0.013/NS
LDL cholesterol (mg/dl) 117.89  38.26 102.89  33.80 94.23  28.77 114.70  39.12 NS
M/BW (mg  kg body wt
1  min
1) 8.85  2.27 7.21  2.86 5.91  2.19 4.47  2.37 0.001/0.003
M/FFM (mg  kg FFM
1  min
1) 11.41  3.06 9.54  3.75 9.64  3.33 7.07  3.23 0.003/0.002
hsIL-6 (pg/ml) 0.74  0.73 0.85  0.83 0.85  0.37 1.16  0.74 0.007/NS
sIL-6R (ng/ml) 48.14  21.94 37.53  14.65 46.15  13.03 36.55  11.96 NS/0.003
sgp130 (ng/ml) 309.96  42.31 367.01  81.54 369.53  61.03 402.03  53.26 0.001/0.001
hsCRP (mg/l) 0.47  0.22 0.67  0.50 1.20  0.83 1.16  0.74 0.001/NS
Data are means  SD unless otherwise indicated. P values are derived from factorial ANOVA. All interactions between PCOS status and
obesity are nonsigniﬁcant. Postload glucose and insulin refer to value at 120 min of the oral glucose tolerance test.
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P  0.002, and r  0.29, P  0.002, respectively), triglyc-
erides (r  0.20, P  0.032), hsCRP (r  0.24, P  0.012),
and free androgen index (r  0.28, P  0.002). We also
observed the signiﬁcant inverse correlation of sgp130 with
insulin sensitivity (r  0.36, P  0.0001) (Fig. 1) and
SHBG (r  0.23, P  0.015). In the subgroup analysis, the
correlation between serum sgp130 and insulin sensitivity
was present in the PCOS subjects (r  0.34, P  0.002)
but not in the control group (r  0.16, P  0.35).
Using M value normalized for body weight (M/BW)
instead of M/FFM increased the effect of obesity (Table 1)
and the correlation with sgp130 was slightly stronger (r 
0.40, P  0.001).
Serum sIL-6R was related to follicle-stimulating hor-
mone in the entire study group (r  0.23, P  0.017) and
in the subgroup of PCOS women (r  0.24, P  0.041).
In multiple regression analysis, we observed that the
relationship between sgp130 and insulin sensitivity was
independent of BMI, waist, percent of body fat, postload
glucose and insulin, triglycerides, and hsCRP (all adjusted
 values between 0.23 and 0.33, all P  0.05), whereas
correlations of sgp130 with SHBG and free androgen index
disappeared after controlling for insulin sensitivity.
Exclusion of subjects with the highest values of post-
load insulin did not change any of the results.
DISCUSSION
The main ﬁnding of the present study is an increased
serum sgp130 concentration in obesity and PCOS and an
inverse relationship between sgp130 and insulin sensitivity
in PCOS women.
So far, serum sgp130 has not been determined in obesity
and PCOS. Escobar-Morreale et al. (18) did not ﬁnd the
difference in circulating sgp130 between control and hy-
perandrogenic women; however, almost 40% of subjects in
the hyperandrogenic group did not have PCOS. The fron-
tier between PCOS and hyperandrogenism is diffuse; how-
ever, because of the large heterogeneity of PCOS itself,
differences in characteristics of the studied groups are
likely to inﬂuence the results. There are studies showing
the association between polymorphisms in IL-6 or IL-6R
and gp130 genes with clinical characteristics of PCOS and
hyperandrogenism (18,19). Regarding the studied poly-
morphism of the gp130 gene, it did not affect the circulat-
ing level of this factor. In another study, polymorphism at
the gp130 locus was associated with traits of the metabolic
syndrome; however, circulating sgp130 was not reported
(20).
Serum sgp130 was inversely related to insulin sensitivity
in PCOS women. As mentioned, it was hypothesized that
the gp130 cytokine family might exert beneﬁcial effects
and might be useful in the treatment of obesity and insulin
resistance (4). Most gp130 cytokines occur in circulation
in small, usually undetectable, concentrations. It is possi-
ble that they might exert auto- and paracrine effects in
insulin-sensitive tissues, as in experimental studies, where
the ciliary neurotrophic factor was demonstrated to regu-
late metabolic processes in adipocytes and skeletal muscle
cells (4,10). Given the fact that circulating sgp130 acts as
an inhibitor of intracellular gp130 signaling (11), the
correlation observed in our study might reﬂect this inhib-
itory effect.
The question arises as to whether an association
between sgp130 and insulin sensitivity is speciﬁc only
for PCOS. We did not observe a signiﬁcant correlation in
the control group. Other populations with different
clinical characteristics should probably be investigated.
However, sgp130 was also increased in obese insulin-
resistant women without PCOS.
Serum sgp130 was also related to SHBG and free
androgen index; however, these associations were no
longer signiﬁcant after controlling for insulin sensitivity.
IL-6, sIL-6R, and sgp130 might also regulate other repro-
ductive functions, such as granulosa cell survival, fol-
licular growth, development of human preovulatory
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FIG. 1. Correlations between sgp130 and insulin sensitivity in the
whole studied group (n  112). Values of sgp130 are shown on a
log-transformed scale. E, PCOS group; f, control group.
TABLE 2
Hormonal characteristics of the studied groups
Lean Obese
P (obesity/PCOS) Control PCOS Control PCOS
n 18 35 16 43
Estradiol (pmol/l) 299.4  303.78 282.00  267.18 163.98  113.98 245.26  242.32 NS
Follicle-stimulating hormone (IU/l) 5.99  1.25 5.78  1.48 5.56  1.73 5.65  1.39 NS
Luteinizing hormone (IU/l) 6.94  5.56 10.21  5.30 4.25  2.24 8.93  4.01 NS/0.001
Testosterone (nmol/l) 1.79  0.38 2.93  1.11 1.75  0.51 2.83  1.06 NS/0.001
SHBG (nmol/l) 89.51  56.28 59.91  46.74 41.50  18.35 36.20  17.96 0.001/0.011
Free androgen index 2.79  1.73 6.95  4.49 4.69  1.70 9.74  6.19 0.001/0.001
Data are means  SD unless otherwise indicated. P values are derived from factorial ANOVA. All interactions between PCOS status and
obesity are nonsigniﬁcant.
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exclude the possibility that sgp130 inﬂuences other
features of PCOS phenotype, not assessed in the present
study. Nevertheless, these are mainly local actions of
sgp130. In our study, estimation of sgp130 serum con-
centration was performed during the 3–5 days of the
menstrual cycle, and the inﬂuence of sgp130 on endo-
metrium in the proliferative phase of the menstrual
cycle seemed to be relatively weak (21).
There are studies that demonstrate an increase in circu-
lating IL-6 and hsCRP in PCOS (22). However, our results
on the lack of an increase in these parameters in PCOS are
in agreement with other data (23,24).
To our knowledge, decrease in sIL-6R in PCOS was not
reported previously. Polymorphisms in the IL-6R gene
were associated with BMI and characteristics of the met-
abolic syndrome (18,25), but not with hyperandrogenism
(18). The balance between sIL-6R and sgp130 in PCOS
seems to be directed toward an inhibition of IL-6 action;
however, the signiﬁcance of this ﬁnding remains unclear.
In conclusion, our data indicate that serum sgp130 is
inversely and independently associated with insulin sensi-
tivity in women with PCOS. An increased serum sp130 in
obesity and PCOS suggests an inhibition of intracellular
gp130 signaling in insulin-resistant conditions.
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